A new USC Schaeffer Center white paper finds expanded access to anti-obesity medications would lead to significant increases ...

BOSTON, April 02, 2025--knownwell, an in-person and virtual, weight-inclusive primary care and metabolic health company, ...

A Prime Therapeutics analysis of real-world data has found that medical costs for patients taking GLP-1 drugs for obesity had increased by about $1,338 per member, compared with a matched control ...

State lawmakers are considering expanding the types of obesity treatments covered by Nevada Medicaid, including approving ...

GLP-1 agonists remain out of reach for many due to high costs, leading some patients to turn to unsafe compounded versions ...

Eli Lilly's much-anticipated drug for diabetes and obesity, that competes with Ozempic globally, is now in India. Here's what ...

A new University of Michigan study shows that a strong majority of older Americans want health insurance — including Medicare — to cover weight loss medica ...

Eli Lilly launches diabetes and obesity drug Mounjaro in India, offering innovative treatment for metabolic health management ...

Mounjaro, a weight loss drug launched by Eli Lilly in India, could be a game-changer and has been making waves lately. Here's ...

Popular anti-diabetes and obesity drug Mounjaro, containing the active ingredient tirzepatide, is now available in India in a ...

A new USC Schaeffer Center white paper finds expanded access to anti-obesity medications would lead to significant increases in life expectancy and disease-free years while generating a ...